Malaria Vaccine Trials in Tanzania Face Challenges from Aid Cuts

Trials for malaria vaccines are underway in Tanzania, where the disease caused 9.4 million cases and 26,000 deaths in 2024. Worldwide, malaria deaths rose from 598,000 in 2023 to 610,000 in 2024, with three-quarters of fatalities among children under five.

Factors such as climate change and antimicrobial resistance contribute to this increase, according to global data. In the village of Mwavi in Tanzania's Bagamoyo District, residents report a decline in malaria infections over the past five years. Mgeni, a mother of five, stated that infections have fallen by about 90 percent.

The trial involved children, but it has also reduced malaria in adults by blocking parasite transmission. Dr Angela Gwakisa, the clinician overseeing the work in Bagamoyo District, confirmed a reduction in malaria cases based on data, with improvements after booster doses.

Amina, a resident and mother of two whose child participated, noted a significant decrease in illness frequency among children in the trial. The R21 vaccine works by preventing mosquitoes from becoming infective after biting infected individuals. Residents have expressed appreciation for the trial's impact, with one mother giving Dr Gwakisa 21 pineapples as a gift.

The trial is nearing completion, and results will be submitted to medical authorities for assessment.

health services rely on foreign aid, which has decreased, particularly from the U.S. and the U.K. The closure of programs by the U.S. Agency for International Development led to a loss of $216 million in aid to Tanzania, affecting 5,000 healthcare workers involved in HIV and malaria prevention.

Residents report that USAID-branded vehicles no longer distribute mosquito nets, and some malaria medications are less available. A research scientist overseeing a trial for the RTSS vaccine developed by GlaxoSmithKline stated that aid cuts will continue to affect Tanzania's health system.

He noted that the government has reorganized finances to cover funding losses.

Dr Brian Tarimo, working on a project for genetically engineered mosquitoes, described a trickle-down effect from the aid cuts. Dr Sarah Moore, evaluating mosquito control products, reported halved consultancy fees and fewer PhD students due to funding shortages.

Dr Gwakisa stated that the R21 vaccine is safe based on trial data, but questions remain about government budgeting for its inclusion in routine immunizations. Rollouts have begun in countries like Nigeria and Ghana.